Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Altravax has received two SBIR grants totaling $1.2m from the NIH’s National Institute of Allergy and Infectious Diseases for research on antibody-inducing vaccines for HIV-1.
Subscribe to our email newsletter
Altravax is expected to use its proprietary MolecularBreeding directed evolution technology to create vaccines that provide protection against the various strains of HIV-1.
Altravax has received exclusive rights to the MolecularBreeding technology platform for the development of vaccines to infectious diseases from Maxygen in January 2010.
Altravax chief scientific officer Robert Whalen said that their past research activities have made progress in developing new vaccine antigens to target the numerous HIV-1 strains and they were pleased that the NIH is continuing to support their research on HIV vaccines.
Altravax also recently received a third NIH SBIR grant for $600,000 to support its research on ‘Improved Vaccines for Influenza B Virus’ to create vaccines that provide protection against the two influenza B virus strains that co-circulate each flu season.